Biopharma News : Biopharma and Pharma news from all around the world :
- Monsanto unanimously wins first Roundup™ trial since U.S. Supreme Court decision
- University Eye Center Los Angeles and Walgreens Offer Free Flu Shots for Uninsured and Underinsured LA Residents This November
- Avanzanite Bioscience Expands UK Presence and Appoints Sarah O’Connell as Country Manager
- Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer
- Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027
- MedTech Innovator Asia Pacific Names Ardens Lifescience 2026 Grand Prize Winner
- AimedBio and Boehringer Ingelheim initiate Phase I study of antibody-drug conjugate BI 4060107
- Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva
- Aptar Pharma Acquires Pulmotree, Expanding Growth Opportunities in Next-Generation Pulmonary Drug Delivery
- VeriSIM Life Powers the AI Behind Next-Generation Cell Preservation
- Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
- Las Vegas Rallies for City of Hope’s First Walk for Hope in the City, Raising Funds for Lifesaving Cancer Research
- Impulse London to Premiere Chemsex Documentary Chemtrail: The Journey at Rich Mix
- Meta Cell Technology Brings Together International Medical Educators for First MCT Academy – Train the Trainers
- Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer
- KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
- Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling
- PharmaEssentia to Present Early-Stage Pipeline Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, Highlighting Immuno-Oncology Approaches for Solid Tumors
- Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026
- BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5
- Spotlight Medical Announces Successful Independent Evaluation of Its Digital Slide-Based Test for Assessing Recurrence Risk in Early Breast Cancer
- Bonerge Lifescience to Launch BonFusion™ and BonVesio™ Precision Delivery Platforms at SupplySide Global 2026
- Prilenia and Ferrer Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington’s Disease
- Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington’s Disease
- Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance
- First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication
- Sensorion Announces the Appointment of Peter Weber, MD, MBA, as Chief Medical Officer
- IMU and UK Biobank to generate the world’s most detailed, large-scale picture of the human immune system for advancing research into health and disease
- PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026
- Genentech to Present Pivotal Data at ESMO 2026, Showcasing Advances Across Its Lung and Breast Cancer Late-Stage Portfolio
News about Biotech, Pharma, Biopharma, Medical Devices, Diagnostics, Digital Health
- Cantourage Further Expands Its Leading Market Position: Premium Producer LOT420 Receives EU-GMP Certification
- Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026
- Drägerwerk AG & Co. KGaA: Dräger with higher net sales and earnings in the first nine months of 2026
- Evotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026
- BioVersys announces first patient first visit in Phase 2b RIV-CARE trial of BV100
- NVision Unveils First Manufacturable Molecular Qubit, Breakthrough Validated in Peer-Reviewed Nature Paper
- Eckert & Ziegler Receives GMP Certificate for Actinium-225
- DEBRA Research Invests in Topadur to Advance Small-Molecule Therapies for Dystrophic Epidermolysis Bullosa
- Straumann Group accelerates organic growth to 9.2% and confirms full-year 2026 outlook
- BIO-Europe 2026 to Convene Global Biopharma Leaders in Cologne as Dealmaking Confidence Grows
- PolyPeptide announces results of the extraordinary general meeting of shareholders
- Galenica successfully places a bond of over CHF 200 million
- Viromed Medical AG: Successful Completion of Capital Increase
- Bronwyn Brophy O’Connor to become CEO of Carl Zeiss Meditec Group in December 2026
- Viromed Medical AG resolves to conduct a capital increase through a cash contribution, excluding shareholders’ subscription rights
- Galenica continues growth trajectory and confirms outlook for 2026
- Newron Completes Enrollment of Pivotal Phase 3 ENIGMA-TRS 1 Study
- Sartorius Stedim Biotech delivers strong operational growth and robust profitability
- BioVersys’ BV100 Phase 2 exploratory data selected for rapid fire and poster presentations at IDWeek 2026
- Sartorius continues its positive growth and margin trajectory with strong nine-month performance
- CorTec Brain Interface Electrodes Record Stable Signals for More Than Four Years
- Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting
- Formycon and Biocelys Combine Complementary Development and Manufacturing Expertise in New Biosimilar Project FYB286
- Cellbox Solutions Completes Series A Financing with Total Proceeds of EUR 5 Million
- BioVersys announces publication of BV100 lung penetration and drug interaction data in two leading peer-reviewed antimicrobial journals
- Cantourage Group SE: Supervisory Board Resolves to Transition to IFRS Following First-Time Requirement to Prepare Consolidated Financial Statements
- Pentixapharm Holding AG: 2026 Earnings Guidance Raised; First-Patient Enrollment in PANDA Phase 3 Study Now Expected in the First Quarter of 2027
- Immunic Appoints Jaa Roberson as Chief People Officer
- Pentixapharm Highlights Growing International Evidence Supporting Phase 3 PANDA Study in Primary Aldosteronism at EANM 2026
- FamiCord AG: intends capital increase of up to 20 percent against cash contri-butions with subscription rights
- INB.bio Launches 2026 Growth Strategy With New Market Entries Across Africa, MENA and Southeast Asia
- HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
- Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026
- Akemi Hair Glow Claims Evaluated: 2026 Hair Growth Transparency Report Examines DHT-Blocking Spray Research, “56% Thicker Hair” Data, and Ingredient Research for Women
- IBA Launches myQAMatriXXAiR to Advance Patient‑Specific QA in Particle Therapy
- Financière de Tubize – Annual report 2025
- Garaherb Claims Evaluated: Complete Scientific Investigation of Ingredients’ Effectiveness
- Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
- Disclosure of a transparency notification from Aberdeen Group plc
- SafeSpace Global Corporation Reports Q2 Fiscal 2026 Financial Results; Company Transitions from Pre-Revenue to Revenue-Generating Stage, Expands Footprint with Nashville Office, and Initiates Steps Toward National Exchange Uplisting
- Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
- Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
- Longeviti Neuro Solutions Appoints T. Rowe Price CEO Robert W. Sharps to Board of Directors
- BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT
- RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET
- WallabyPhenox Announces First U.S. Patient Treated with p48 & p64 MW HPC Flow Modulation Devices in PIANO IDE Trial
- Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis
- Picard Medical / SynCardia to Present its Next-Generation Emperor Total Artificial Heart Technology at the American College of Cardiology’s Annual Scientific Session
- Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026
- Human Appeal to deliver food aid to thousands of displaced civilians as part of initial response in Lebanon
- BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026
- BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026
- Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update
- Pacific Health Care Organization, Inc. Reports its 2025 Year-End Financial Results
- Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
- BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025
- New partnership to fast-track Canadian health technology from innovation to patient care
- Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue Projected; Important R&D Updates Expected Following Finalization of Certain Anticipated Transactions
- Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue Projected; Important R&D Updates Expected Following Finalization of Certain Anticipated Transactions
- New partnership to fast-track Canadian health technology from innovation to patient care
Sources for this page of Biopharma News : biopharma-reporter.com and worldpharmanews and pharmatimes.com and drugs.com and fiercepharma.com and scripintelligence.com and PR Newswire and Business Wire. Please visit all this very interesting websites for more info.
Biopharma News – Pharma News